Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 2
1991 3
1992 2
1993 1
1994 5
1995 6
1996 16
1997 23
1998 40
1999 35
2000 38
2001 34
2002 25
2003 42
2004 51
2005 29
2006 29
2007 35
2008 45
2009 43
2010 31
2011 25
2012 33
2013 35
2014 29
2015 30
2016 27
2017 22
2018 29
2019 22
2020 27
2021 25
2022 12
2023 22
2024 21
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

839 results

Results by year

Filters applied: . Clear all
Page 1
Clinical pharmacokinetics of dorzolamide.
Martens-Lobenhoffer J, Banditt P. Martens-Lobenhoffer J, et al. Clin Pharmacokinet. 2002;41(3):197-205. doi: 10.2165/00003088-200241030-00004. Clin Pharmacokinet. 2002. PMID: 11929320 Review.
Dorzolamide is a carbonic anhydrase inhibitor for topical ophthalmic application. It is used in the treatment of glaucoma to lower the intraocular pressure. ...This review summarises the pharmacokinetic and pharmacodynamic properties of dorzolamide and its metabolit
Dorzolamide is a carbonic anhydrase inhibitor for topical ophthalmic application. It is used in the treatment of glaucoma to lower th
Nephrolithiasis with dorzolamide.
Carlsen J, Durcan J, Zabriskie N, Swartz M, Crandall A. Carlsen J, et al. Arch Ophthalmol. 1999 Aug;117(8):1087-8. doi: 10.1001/archopht.117.8.1087. Arch Ophthalmol. 1999. PMID: 10448757 No abstract available.
Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma.
Ormrod D, McClellan K. Ormrod D, et al. Drugs Aging. 2000 Dec;17(6):477-96. doi: 10.2165/00002512-200017060-00005. Drugs Aging. 2000. PMID: 11200308 Review.
The nonselective beta-blocker timolol and the carbonic anhydrase inhibitor dorzolamide both lower intraocular pressure (IOP). Timolol and dorzolamide have different mechanisms of action and their effects are additive when administered together. ...Clinical trials in …
The nonselective beta-blocker timolol and the carbonic anhydrase inhibitor dorzolamide both lower intraocular pressure (IOP). Timolol …
Dorzolamide intermediates with potential anti-inflammatory activity.
Atre R, Obukhov AG, Majmudar CY, Nair K, White FA, Sharma R, Siddiqi F, Faisal SM, Varma VP, Hassan MI, Mohammad T, Darwhekar GN, Baig MS. Atre R, et al. Eur J Pharmacol. 2025 Jan 15;987:177160. doi: 10.1016/j.ejphar.2024.177160. Epub 2024 Dec 2. Eur J Pharmacol. 2025. PMID: 39631651
Dorzolamide (DZD), a Carbonic anhydrase (CA) inhibitor clinically used to lower intraocular pressure, exhibits anti-inflammatory effects owing to the drug's ability to inhibit the TIR domain-containing adaptor protein (TIRAP)-mediated signalling in macrophages. ...
Dorzolamide (DZD), a Carbonic anhydrase (CA) inhibitor clinically used to lower intraocular pressure, exhibits anti-inflammatory effe
Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study.
Inatani M, Orii Y, Iwasaki K, Arimura S, Sunagawa H, Shiokawa M, Inoue K, Sakono T, Sakono T, Kuwamura R, Yoshida A, Oi J, Kuwayama Y, Kano K, Kido N, Matsuyama A, Ozaki M, Abe H, Inoue C, Nakagawa S, Musashi K, Kanamori A, Lee J, Otani S, Aoki R, Tanabe H, Nakakura S, Suzuki K, Sagara T, Saito Y, Sameshima M, Urahashi M, Watanabe-Kitamura F, Inoue T, Kagaya F, Murai Y, Mori S, Ueda K, Kurimoto T, Yamada-Nakanishi Y, Nakamura M, Yamashita T, Ishiyama S, Manabe S, Takaki K, Hayashi K, Ishida A, Tsutsui A, Manabe K, Tanito M. Inatani M, et al. Adv Ther. 2023 Sep;40(9):4074-4092. doi: 10.1007/s12325-023-02589-9. Epub 2023 Jul 15. Adv Ther. 2023. PMID: 37452961 Free PMC article. Clinical Trial.
INTRODUCTION: This multicenter, randomized, comparative, and investigator-masked crossover clinical trial sought to compare the efficacy and tolerability of fixed combinations of 0.1% brimonidine/0.5% timolol (BTFC) versus 1% dorzolamide/0.5% timolol (DTFC) as adjunctive t …
INTRODUCTION: This multicenter, randomized, comparative, and investigator-masked crossover clinical trial sought to compare the efficacy and …
Topical drug delivery to the eye: dorzolamide.
Loftsson T, Jansook P, Stefánsson E. Loftsson T, et al. Acta Ophthalmol. 2012 Nov;90(7):603-8. doi: 10.1111/j.1755-3768.2011.02299.x. Epub 2012 Jan 23. Acta Ophthalmol. 2012. PMID: 22269010 Free article. Review.
The solid dorzolamide/gammaCD microparticles are mucoadhesive and release dorzolamide into the aqueous tear fluid for extended time period. Consequently, sustained high dorzolamide concentrations in aqueous humour and various eye tissues were observed after s …
The solid dorzolamide/gammaCD microparticles are mucoadhesive and release dorzolamide into the aqueous tear fluid for extended …
Risk factors for periorbital dermatitis in patients using dorzolamide/timolol eye drops.
Kim M, Jang H, Rho S. Kim M, et al. Sci Rep. 2021 Sep 9;11(1):17896. doi: 10.1038/s41598-021-97565-0. Sci Rep. 2021. PMID: 34504268 Free PMC article.
This study assessed the clinical risk factors for periorbital dermatitis (PD) after using dorzolamide/timolol eye drops in a total of 1282 glaucoma patients. Both the PD(+) group and the PD(-) group were evaluated using clinical data such as age, sex, …
This study assessed the clinical risk factors for periorbital dermatitis (PD) after using dorzolamide/timolol eye drops in a t …
Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension.
Balfour JA, Wilde MI. Balfour JA, et al. Drugs Aging. 1997 May;10(5):384-403. doi: 10.2165/00002512-199710050-00006. Drugs Aging. 1997. PMID: 9143858 Review.
Dorzolamide (dorzolamide hydrochloride), the first topical carbonic anhydrase (CA) inhibitor to become available for clinical use, lowers intraocular pressure (IOP) by reducing aqueous humour formation. ...The most common adverse effects associated with dorzolami
Dorzolamide (dorzolamide hydrochloride), the first topical carbonic anhydrase (CA) inhibitor to become available for clinical
Allergic contact dermatitis due to dorzolamide eyedrops.
Mitsuyama S, Abe F, Higuchi T. Mitsuyama S, et al. Contact Dermatitis. 2021 Jan;84(1):58-59. doi: 10.1111/cod.13671. Epub 2020 Aug 24. Contact Dermatitis. 2021. PMID: 32700819 No abstract available.
Dorzolamide-induced relaxation of isolated rabbit ciliary arteries mediated by inhibition of extracellular calcium influx.
Dong Y, Sawada Y, Cui J, Hayakawa M, Ogino D, Ishikawa M, Yoshitomi T. Dong Y, et al. Jpn J Ophthalmol. 2016 Mar;60(2):103-10. doi: 10.1007/s10384-015-0423-z. Epub 2016 Jan 12. Jpn J Ophthalmol. 2016. PMID: 26759121
PURPOSE: The carbonic anhydrase inhibitor dorzolamide can increase optic nerve blood flow. The aim of the study reported here was to investigate the effect of dorzolamide on isolated rabbit ciliary arteries that supply the optic nerve. ...Furthermore, 3 mM dorzol
PURPOSE: The carbonic anhydrase inhibitor dorzolamide can increase optic nerve blood flow. The aim of the study reported here was to …
839 results